Gary Patou, M.D.
San Francisco Office
Gary Patou, M.D., joined MPM in 2005 and now serves as the Head of Clinical for Chiasma Pharmaceuticals. Gary has served as interim Chief Medical Officer in various MPM portfolio companies, including Pacira Pharmaceuticals (PCRX) and Peplin, Ltd., where he took a leading role in gaining FDA approval for Exparel® and Picato®, respectively.
Prior to joining MPM, Gary was Executive Vice President and Chief Medical Officer of Oscient Pharmaceuticals, Inc., following its merger with GeneSoft Pharmaceuticals in 2004. As President of GeneSoft, Gary was instrumental in applying for and obtaining FDA approval of the company’s lead product, Factive®. Before GeneSoft, Gary worked at SmithKline Beecham Pharmaceuticals (now a unit of GlaxoSmithKline: GSK) as Senior Vice President & Director, Project and Portfolio Management, managing all of the company’s pharmaceutical development projects, including the FDA-approved products Paxil® and Augmentin®. Gary also served as Director and Vice President of Anti-Infective Development where he managed the development of a broad line of anti-infective products, including oral, IV and topical antibiotics.
Gary has held a number of academic appointments at University College & Middlesex School of Medicine in London and holds an M.D. degree from University College, London.